
Sign up to save your podcasts
Or


Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937
By BMJ Group4.2
99 ratings
Elizabeth Highton (JNNP Podcast Editor) speaks with Dr. Michelle Farrar (University of New South Wales) discussing nusinersen, the first disease-modifying therapy for spinal muscular atrophy type 1 (SMA). https://jnnp.bmj.com/content/89/9/937

504 Listeners

40 Listeners

49 Listeners

299 Listeners

5 Listeners

9 Listeners

7 Listeners

4 Listeners

2 Listeners

3 Listeners

26 Listeners

41 Listeners

14 Listeners

1 Listeners

53 Listeners

0 Listeners

6 Listeners

15 Listeners

3 Listeners

26 Listeners

23 Listeners

134 Listeners

1,314 Listeners

80 Listeners

0 Listeners